Efficacy
Crohn’s Disease Activity
REMISSION
Clinical response was observed in 53.8% (56/104) and 41.3% (43/104) of patients at weeks 56 and 112, respectively (Fig. Clinical response and remission rates in patients receiving brazikumab during the open-label period. Nonresponder imputation used for missing data. Clinical response was defined as a CDAI total score < 150 or reduction from baseline in CDAI score of ≥ 100 points. Clinical remission was defined as a CDAI total score < 150. CDAI, Crohn’s Disease Activity Index